Compare Procter & Gamble Health with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs PANACEA BIOTECH - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH PANACEA BIOTECH PROCTER & GAMBLE HEALTH/
PANACEA BIOTECH
 
P/E (TTM) x 51.5 12.6 408.6% View Chart
P/BV x 4.7 3.0 153.9% View Chart
Dividend Yield % 10.2 0.0 -  

Financials

 PROCTER & GAMBLE HEALTH   PANACEA BIOTECH
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
PANACEA BIOTECH
Mar-18
PROCTER & GAMBLE HEALTH/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs3,549364 975.0%   
Low Rs1,301129 1,008.0%   
Sales per share (Unadj.) Rs511.496.8 528.4%  
Earnings per share (Unadj.) Rs61.3-12.4 -493.9%  
Cash flow per share (Unadj.) Rs74.0-2.9 -2,594.9%  
Dividends per share (Unadj.) Rs440.000-  
Dividend yield (eoy) %18.10-  
Book value per share (Unadj.) Rs927.850.4 1,840.9%  
Shares outstanding (eoy) m16.6061.25 27.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.5 186.1%   
Avg P/E ratio x39.6-19.9 -199.1%  
P/CF ratio (eoy) x32.8-86.4 -37.9%  
Price / Book Value ratio x2.64.9 53.4%  
Dividend payout %717.90-   
Avg Mkt Cap Rs m40,25715,101 266.6%   
No. of employees `0001.12.5 45.9%   
Total wages/salary Rs m1,3131,516 86.6%   
Avg. sales/employee Rs Th7,486.72,401.9 311.7%   
Avg. wages/employee Rs Th1,157.6614.2 188.5%   
Avg. net profit/employee Rs Th897.2-307.9 -291.3%   
INCOME DATA
Net Sales Rs m8,4905,928 143.2%  
Other income Rs m24482 296.4%   
Total revenues Rs m8,7346,010 145.3%   
Gross profit Rs m1,482845 175.3%  
Depreciation Rs m211585 36.1%   
Interest Rs m01,006 0.0%   
Profit before tax Rs m1,514-664 -228.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m56399 570.5%   
Profit after tax Rs m1,017-760 -133.9%  
Gross profit margin %17.514.3 122.4%  
Effective tax rate %37.1-14.9 -250.0%   
Net profit margin %12.0-12.8 -93.5%  
BALANCE SHEET DATA
Current assets Rs m15,3435,603 273.8%   
Current liabilities Rs m1,9606,910 28.4%   
Net working cap to sales %157.6-22.0 -715.1%  
Current ratio x7.80.8 965.3%  
Inventory Days Days49206 23.7%  
Debtors Days Days2884 34.0%  
Net fixed assets Rs m1,2099,941 12.2%   
Share capital Rs m16661 270.8%   
"Free" reserves Rs m15,2353,026 503.5%   
Net worth Rs m15,4013,087 498.9%   
Long term debt Rs m05,707 0.0%   
Total assets Rs m17,59516,076 109.4%  
Interest coverage xNM0.3-  
Debt to equity ratio x01.8 0.0%  
Sales to assets ratio x0.50.4 130.9%   
Return on assets %5.81.5 378.2%  
Return on equity %6.6-24.6 -26.8%  
Return on capital %10.33.9 261.9%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m1,6361,600 102.3%   
Fx outflow Rs m4,3681,131 386.1%   
Net fx Rs m-2,732469 -583.0%   
CASH FLOW
From Operations Rs m-1,3041,180 -110.5%  
From Investments Rs m12,697553 2,296.5%  
From Financial Activity Rs m-301-1,644 18.3%  
Net Cashflow Rs m11,09390 12,366.7%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 0.6 3,033.3%  
FIIs % 1.0 1.3 76.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 23.6 123.3%  
Shareholders   28,591 10,259 278.7%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Sep 13, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH - IPCA LABS COMPARISON

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS